At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 44 enrolled
Drug / intervention
MEDI9314 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1a Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI9314 in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating MEDI9314 and placebo for Safety and Healthy Subjects. Completed, enrolled 44 participants across 2 sites in 2 countries.
Detailed Summary
This is a phase 1a randomized, blinded, placebo-controlled, single-ascending dose study to assess the safety and tolerability of MEDI9314 in healthy adult subjects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSafety, Healthy Subjects
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartFeb 2016
Primary CompletionNov 2016
Study CompletionJun 2017
TodayJul 2026
First PostedFeb 1, 2016
Enrollment StartFeb 18, 2016
Primary CompletionNov 17, 2016
Study CompletionJun 12, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.4 years ago
Interventions
MEDI9314drug
single dose of MEDI9314
placebodrug
single dose of placebo